Last checked at 16 Apr 2013 07:00
For immediate release | 16 April 2013 |
Futura Medical plc
("Futura" or "the Company")
Director Share Dealings
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, received notification on 15 April 2013 from James Barder, the Chief Executive of the Company, that his non-beneficial interest in the Company has increased from 309,000 ordinary shares to 352,500 ordinary shares as a result of a purchase, by a family trust of which Mr Barder is a trustee, of 43,500 ordinary shares at 65 pence per share on 15 April 2013.
Mr Barder's aggregate beneficial and non-beneficial holding has therefore increased from 925,330 ordinary shares to 968,830 ordinary shares representing 1.25% of the Company's issued share capital.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com